Arakis is a biopharmaceutical company that specializes in discovery, development and commercialization of products based on novel clinical uses of established drugs, thus reducing the risks associated with development. The company focuses on inflammatory disease and cancer adjunctive therapies including pain. Arakis' business strategy is to develop primary care products to the end of Phase II and then to out-license them to appropriate development and marketing partners. The company’ products include AD 237, AD 452, AD 337 etc.